Guilford (GLFD) - Steadily Rising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve who wrote (270)	3/25/1999 12:58:00 PM
From: LLCF	Read Replies (2) of 496

Insider buyers: Guilford Pharmaceutical (GLFD: $10.38) This biopharmaceutical company develops products that treat cancer. The company also makes therapeutic products for the treatment of neurological diseases. The stock trades at 1.4 times book value, 1.6 times cash and near the 12-month low. Despite news that the company purchased 100,000 common shares and the fact that members of the management team picked up 12,500 shares at an average price of $10.13 since February had little effect on the stock. Wall Street expects the company to lose $1.16 per share for the year ending December 1999 and to lose $0.97 per share in FY 200 DAK

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next